Nuformix plc (LON:NFX – Get Free Report) fell 12% on Wednesday . The company traded as low as GBX 0.41 and last traded at GBX 0.43. 243,141,344 shares changed hands during mid-day trading, an increase of 321% from the average session volume of 57,801,742 shares. The stock had previously closed at GBX 0.49.
Nuformix Stock Up 2.7%
The firm has a market capitalization of £7.72 million, a P/E ratio of -0.97 and a beta of 1.22. The firm has a 50 day moving average of GBX 0.22 and a 200-day moving average of GBX 0.14.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Recommended Stories
- Five stocks we like better than Nuformix
- Conference Calls and Individual Investors
- CAVA Stock Looking for Direction After Earnings Miss
- What Are Some of the Best Large-Cap Stocks to Buy?
- 3 Small AI Stocks Ready to Explode (All Under $20)
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- After 16% Fall, Analysts Eye a Big Recovery in Meta Platforms
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
